PROVECTUS BIOPHARMACEUTICALS, INC. Operating Lease Right-of-Use Assets
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) had Operating Lease Right-of-Use Assets of $102.55 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Operating Lease, Right-of-Use Asset $102.55K.
- 2026-03-31: Operating Lease, Right-of-Use Asset $114.66K.
- 2025-12-31: Operating Lease, Right-of-Use Asset $126.63K.
- 2025-09-30: Operating Lease, Right-of-Use Asset $138.45K.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $102.55K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $114.66K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $126.63K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $138.45K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $150.13K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $12.39K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $24.62K 10-K · filed 2026-03-26 |
| 2024-09-30 | $36.70K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $48.62K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $60.40K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $72.03K 10-K · filed 2025-03-28 |
| 2023-09-30 | $83.51K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $94.85K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $106.05K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $117.12K 10-K · filed 2024-03-28 |
| 2022-09-30 | $128.06K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $138.86K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $15.18K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $39.56K 10-K · filed 2023-03-30 |
| 2021-09-30 | $58.74K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $80.81K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $100.81K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $120.82K 10-K · filed 2022-03-29 |
| 2020-09-30 | $139.21K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $157.60K 10-Q · filed 2020-08-12 |
| 2020-03-31 | $176.44K 10-Q · filed 2020-05-13 |
| 2019-12-31 | $194.40K 10-K · filed 2021-03-02 |
| 2019-09-30 | $212.19K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $229.97K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $247.76K 10-Q · filed 2019-05-13 |